Premium
Photoacoustic Imaging Quantifies Drug Release from Nanocarriers via Redox Chemistry of Dye‐Labeled Cargo
Author(s) -
Jeevarathinam Ananthakrishnan Soundaram,
Lemaster Jeanne E.,
Chen Fang,
Zhao Eric,
Jokerst Jesse V.
Publication year - 2020
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201914120
Subject(s) - nanocarriers , chemistry , plga , paclitaxel , in vivo , conjugate , redox , methylene blue , biophysics , photoacoustic imaging in biomedicine , in vitro , conjugated system , nanoparticle , controlled release , drug delivery , pharmacology , biochemistry , nanotechnology , organic chemistry , cancer , materials science , mathematics , mathematical analysis , optics , biology , microbiology and biotechnology , photocatalysis , catalysis , medicine , physics , polymer
We report a new approach to monitor drug release from nanocarriers via a paclitaxel–methylene blue conjugate (PTX‐MB) with redox activity. This construct is in a photoacoustically silent reduced state inside poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles (PTX‐MB@PLGA NPs). During release, PTX‐MB is spontaneously oxidized to produce a concentration‐dependent photoacoustic signal. An in vitro drug‐release study showed an initial burst release (25 %) between 0–24 h and a sustained release between 24–120 h with a cumulative release of 40.6 % and a 670‐fold increase in photoacoustic signal. An in vivo murine drug release showed a photoacoustic signal enhancement of up to 649 % after 10 hours. PTX‐MB@PLGA NPs showed an IC 50 of 78 μg mL −1 and 44.7±4.8 % decrease of tumor burden in an orthotopic model of colon cancer via luciferase‐positive CT26 cells.